Pain is one of the main symptoms reported by sick children, particularly by those suffering from cancer. Opioids are very useful in controlling this symptom but they are burdened with significant side effects that limit their use in children. Buprenorphine is a strong opioid that, due to its particular pharmacological characteristics, ensures excellent pain relief with fewer side effects than other opioids. The transdermal formulation allows for good pain control associated with optimal compliance by patients and few limitations on daily life. Unfortunately, transdermal buprenorphine use remains off-label for the control of chronic pain in children; therefore, it is desirable that new studies can validate its use in the paediatric population. This review aims to analyse the clinical advantages of transdermal buprenorphine in the paediatric population and the possible side effects registered in daily clinical practice.

Attina, G., Romano, A., Triarico, S., Mastrangelo, S., Maurizi, P., Ruggiero, A., Transdermal buprenorphine for pain management in children, <<DRUGS IN CONTEXT>>, 2021; 10 (September 14): 1-8. [doi:10.7573/DIC.2021-6-1] [https://hdl.handle.net/10807/223522]

Transdermal buprenorphine for pain management in children

Mastrangelo, Stefano;Maurizi, Palma;Ruggiero, Antonio
2021

Abstract

Pain is one of the main symptoms reported by sick children, particularly by those suffering from cancer. Opioids are very useful in controlling this symptom but they are burdened with significant side effects that limit their use in children. Buprenorphine is a strong opioid that, due to its particular pharmacological characteristics, ensures excellent pain relief with fewer side effects than other opioids. The transdermal formulation allows for good pain control associated with optimal compliance by patients and few limitations on daily life. Unfortunately, transdermal buprenorphine use remains off-label for the control of chronic pain in children; therefore, it is desirable that new studies can validate its use in the paediatric population. This review aims to analyse the clinical advantages of transdermal buprenorphine in the paediatric population and the possible side effects registered in daily clinical practice.
Inglese
Attina, G., Romano, A., Triarico, S., Mastrangelo, S., Maurizi, P., Ruggiero, A., Transdermal buprenorphine for pain management in children, <<DRUGS IN CONTEXT>>, 2021; 10 (September 14): 1-8. [doi:10.7573/DIC.2021-6-1] [https://hdl.handle.net/10807/223522]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/223522
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 1
  • ???jsp.display-item.citation.isi??? ND
social impact